Cargando…

Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia

INTRODUCTION. Infectious meningoencephalitis (IME) is a neurological emergency with a significant rate of morbidity and mortality. The Biofire FilmArray® meningitis/encephalitis (FAME) panel for testing in cerebrospinal fluid (CSF) has proven to be a valuable tool for the aetiological diagnosis of I...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero-Hernández, Camilo A., Zuleta-Motta, Jessica L., Zapa-Pérez, Neiry M., Martínez-Lemus, Juan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: EVIDENZE 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662192/
https://www.ncbi.nlm.nih.gov/pubmed/37489856
http://dx.doi.org/10.33588/rn.7704.2023082
_version_ 1785138152797634560
author Romero-Hernández, Camilo A.
Zuleta-Motta, Jessica L.
Zapa-Pérez, Neiry M.
Martínez-Lemus, Juan D.
author_facet Romero-Hernández, Camilo A.
Zuleta-Motta, Jessica L.
Zapa-Pérez, Neiry M.
Martínez-Lemus, Juan D.
author_sort Romero-Hernández, Camilo A.
collection PubMed
description INTRODUCTION. Infectious meningoencephalitis (IME) is a neurological emergency with a significant rate of morbidity and mortality. The Biofire FilmArray® meningitis/encephalitis (FAME) panel for testing in cerebrospinal fluid (CSF) has proven to be a valuable tool for the aetiological diagnosis of IME, facilitating targeted antimicrobial therapy. The aim is to determine the impact of the FAME panel on antimicrobial therapeutic decisions in patients with suspected IME in the first 24 hours of clinical assessment. PATIENTS AND METHODS. This is a descriptive observational study that comments on the clinical manifestations, the neuroimaging and paraclinical findings, and the antibiotic therapy of patients with suspected IME. An analysis was performed to determine the impact of FAME on antimicrobial therapy in the first 24 hours of the clinical assessment of patients. RESULTS. Altogether 44 patients were included. The average time required to obtain the result of the FAME panel for testing in CSF was nine hours, with 20.4% (9/44) of tests yielding positive results. Within 24 hours of clinical assessment, their outcome had an impact on antimicrobial treatment decisions in 75% (33/44) of cases. In patients with a high clinical suspicion of IME, the result of FAME made it possible to change the initial empirical therapy to a targeted therapy in 15% (3/20) of cases and to discontinue the initial empirical therapy in 35% (7/20) of the subjects. In patients with low clinical suspicion of IME, their result allowed 25% (6/24) to have their suspicion confirmed and they were started on targeted antibiotic therapy; in contrast, 70.8% (17/24) had their diagnosis ruled out and were not started on treatment. CONCLUSIONS. The result of the FAME panel for testing in CSF has a high impact on antimicrobial therapeutic decisions within 24 hours of clinical assessment. However, it must be interpreted with the clinical context, local epidemiology and other diagnostic studies.
format Online
Article
Text
id pubmed-10662192
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher EVIDENZE
record_format MEDLINE/PubMed
spelling pubmed-106621922023-08-16 Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia Romero-Hernández, Camilo A. Zuleta-Motta, Jessica L. Zapa-Pérez, Neiry M. Martínez-Lemus, Juan D. Rev Neurol Original INTRODUCTION. Infectious meningoencephalitis (IME) is a neurological emergency with a significant rate of morbidity and mortality. The Biofire FilmArray® meningitis/encephalitis (FAME) panel for testing in cerebrospinal fluid (CSF) has proven to be a valuable tool for the aetiological diagnosis of IME, facilitating targeted antimicrobial therapy. The aim is to determine the impact of the FAME panel on antimicrobial therapeutic decisions in patients with suspected IME in the first 24 hours of clinical assessment. PATIENTS AND METHODS. This is a descriptive observational study that comments on the clinical manifestations, the neuroimaging and paraclinical findings, and the antibiotic therapy of patients with suspected IME. An analysis was performed to determine the impact of FAME on antimicrobial therapy in the first 24 hours of the clinical assessment of patients. RESULTS. Altogether 44 patients were included. The average time required to obtain the result of the FAME panel for testing in CSF was nine hours, with 20.4% (9/44) of tests yielding positive results. Within 24 hours of clinical assessment, their outcome had an impact on antimicrobial treatment decisions in 75% (33/44) of cases. In patients with a high clinical suspicion of IME, the result of FAME made it possible to change the initial empirical therapy to a targeted therapy in 15% (3/20) of cases and to discontinue the initial empirical therapy in 35% (7/20) of the subjects. In patients with low clinical suspicion of IME, their result allowed 25% (6/24) to have their suspicion confirmed and they were started on targeted antibiotic therapy; in contrast, 70.8% (17/24) had their diagnosis ruled out and were not started on treatment. CONCLUSIONS. The result of the FAME panel for testing in CSF has a high impact on antimicrobial therapeutic decisions within 24 hours of clinical assessment. However, it must be interpreted with the clinical context, local epidemiology and other diagnostic studies. EVIDENZE 2023-08-16 /pmc/articles/PMC10662192/ /pubmed/37489856 http://dx.doi.org/10.33588/rn.7704.2023082 Text en Copyright: © Revista de Neurología https://creativecommons.org/licenses/by-nc-nd/4.0/Revista de Neurología trabaja bajo una licencia Creative Commons
spellingShingle Original
Romero-Hernández, Camilo A.
Zuleta-Motta, Jessica L.
Zapa-Pérez, Neiry M.
Martínez-Lemus, Juan D.
Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title_full Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title_fullStr Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title_full_unstemmed Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title_short Experiencia con el Biofire FilmArray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia
title_sort experiencia con el biofire filmarray(®) para meningitis/encefalitis infecciosa en una institución de alta complejidad en bogotá, colombia
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662192/
https://www.ncbi.nlm.nih.gov/pubmed/37489856
http://dx.doi.org/10.33588/rn.7704.2023082
work_keys_str_mv AT romerohernandezcamiloa experienciaconelbiofirefilmarrayparameningitisencefalitisinfecciosaenunainstituciondealtacomplejidadenbogotacolombia
AT zuletamottajessical experienciaconelbiofirefilmarrayparameningitisencefalitisinfecciosaenunainstituciondealtacomplejidadenbogotacolombia
AT zapaperezneirym experienciaconelbiofirefilmarrayparameningitisencefalitisinfecciosaenunainstituciondealtacomplejidadenbogotacolombia
AT martinezlemusjuand experienciaconelbiofirefilmarrayparameningitisencefalitisinfecciosaenunainstituciondealtacomplejidadenbogotacolombia